Ligand Pharmaceuticals Incorporated
LGND
$294.60
$5.782.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 63.69M | 51.72M | 59.67M | 115.46M | 47.63M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 63.69M | 51.72M | 59.67M | 115.46M | 47.63M |
| Cost of Revenue | 17.88M | 5.42M | 6.50M | 24.82M | 9.47M |
| Gross Profit | 45.81M | 46.30M | 53.16M | 90.64M | 38.15M |
| SG&A Expenses | 29.12M | 20.84M | 25.03M | 28.45M | 20.18M |
| Depreciation & Amortization | 8.10M | 8.10M | 8.10M | 8.10M | 8.26M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.10M | 34.35M | 39.63M | 61.36M | 37.91M |
| Operating Income | 8.59M | 17.37M | 20.04M | 54.10M | 9.72M |
| Income Before Tax | 64.30M | -24.26M | 56.78M | 141.14M | 11.22M |
| Income Tax Expenses | 15.80M | -10.91M | 12.00M | 23.86M | 6.38M |
| Earnings from Continuing Operations | 48.51M | -13.35M | 44.78M | 117.27M | 4.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.51M | -13.35M | 44.78M | 117.27M | 4.85M |
| EBIT | 8.59M | 17.37M | 20.04M | 54.10M | 9.72M |
| EBITDA | 16.81M | 25.58M | 28.25M | 62.37M | 18.24M |
| EPS Basic | 2.42 | -0.67 | 2.27 | 5.99 | 0.25 |
| Normalized Basic EPS | 1.64 | 0.66 | 3.70 | 1.83 | 0.33 |
| EPS Diluted | 2.22 | -0.67 | 2.12 | 5.68 | 0.24 |
| Normalized Diluted EPS | 1.50 | 0.66 | 3.45 | 1.74 | 0.32 |
| Average Basic Shares Outstanding | 20.06M | 19.88M | 19.73M | 19.58M | 19.33M |
| Average Diluted Shares Outstanding | 21.84M | 19.88M | 21.14M | 20.63M | 19.93M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |